LifeMD's Analyst Narrative Shifts with Revised Fair Value Estimate and Stronger 2026 Outlook

LifeMD's price target has been revised to $9.88, a 7% increase, due to Q4 revenue and adjusted EBITDA beats, a stronger 2026 outlook, and growing interest in its virtual care push around weight loss management and GLP-1 exposure. Analysts such as Mizuho and H.C. Wainwright have raised their price targets, while Street commentary indicates the thesis is still heavily tied to the weight loss program.